Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017
Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006
Combination of beta2 agonists and anticholinergic drugs improves lung function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 726s Year: 2006
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis Source: Eur Respir J 2011; 37: 1091-1095 Year: 2011
Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Effect of inhaled bronchodilator therapy on the bacterioexcretion and on the quality of life (LQ) of pulmonary TB patients with concomitant lung obstructive syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019 Year: 2019
Effect of inhaled steroids on long term prognosis of lung function in adults with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 664s Year: 2004
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007
The impact of a high fine particle fraction inhaled long acting ß2 agonist (Formoterol) on airway function in asthma: evaluation with oxygen enhanced MRI and multiple breath washout. Source: International Congress 2017 – Imaging markers for COPD and asthma Year: 2017
Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014